ReviewInternational journal of molecular sciences2023
BRCA Mutations-The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Assessing the Clinical Relevance ofCurrent oncology (Toronto, Ont.) · 2026Article
- Recent Advances (2020-2025) in Estrogen and ER-Positive Breast Cancer: Receptor Signaling, Tumor Microenvironment, Endocrine Therapy Resistance and Innovative Treatment Strategies-A Comprehensive Review.Cancer management and research · 2026Review
- Functional analysis of BRCA1 and BRCA2 splicing variants using a minigene assay.Human genomics · 2025Article
- Poly(ADP-ribose) polymerase-1 in breast cancers: expression level and its association in various molecular subtypes with a focus in Africa.Discover oncology · 2025Review
- Clinical applications of next-generation sequencing-based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression.Molecular oncology · 2025Review
- Serine/threonine kinase 11 (STK11) associated adnexal tumors: from biology to therapeutic impact.Human genomics · 2025Review
- DS-MVP: identifying disease-specific pathogenicity of missense variants by pre-training representation.Briefings in bioinformatics · 2025Article
- Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.Pathogens (Basel, Switzerland) · 2025Review
- BRCA1 and BRCA2 as prognostic markers in oral squamous cell carcinoma: a minireview.Frontiers in oncology · 2025Review
- From precursor to cancer: decoding the intrinsic and extrinsic pathways of pancreatic intraepithelial neoplasia progression.Carcinogenesis · 2024Review
- Risk Factors for Ovarian Cancer in South America: A Literature Review.Journal of personalized medicine · 2024Review
- Advances in Personalized Oncology.Cancers · 2024Review
- A Molecular Characterization of the Allelic Expression of theInternational journal of molecular sciences · 2024Article
- Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery.Biomedicines · 2024Review
- Reproductive outcomes in women with BRCA 1/2 germline mutations: A retrospective observational study and literature review.Open medicine (Warsaw, Poland) · 2024Article
- The Epigenetic Reader Methyl-CpG-Binding Protein 2 (MeCP2) Is an Emerging Oncogene in Cancer Biology.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Two related tumor suppressor genes,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.